Author: Savosina, P. I.; Druzhilovskii, D. S.; Poroikov, V. V.
Title: COVID-19: Analysis of Drug Repositioning Practice Cord-id: p5kt1g1d Document date: 2021_1_11
ID: p5kt1g1d
Snippet: An outbreak of a new coronavirus disease (COVID-19) in China in December 2019 became the epicenter for the spread of a global pandemic. The SARS-CoV-2 coronavirus causes a cascade of respiratory diseases similar to severe acute respiratory syndrome (SARS). Currently, there is no effective, specific, and safe treatment for COVID-19 to suppress the virus in the human body. The present study searched for pharmacological substances with antiviral activity for possible drug repositioning based on exp
Document: An outbreak of a new coronavirus disease (COVID-19) in China in December 2019 became the epicenter for the spread of a global pandemic. The SARS-CoV-2 coronavirus causes a cascade of respiratory diseases similar to severe acute respiratory syndrome (SARS). Currently, there is no effective, specific, and safe treatment for COVID-19 to suppress the virus in the human body. The present study searched for pharmacological substances with antiviral activity for possible drug repositioning based on experimental and theoretical information in a series of publications on in vitro assays of agents against SARS-CoV-2. An analysis identified 46 well-known pharmaceutical substances that could be used for drug repositioning to create a therapy for COVID-19.
Search related documents:
Co phrase search for related documents- action different mechanism and additional therapy: 1
- active compound and acute respiratory distress syndrome: 1, 2
- active metabolite and acute respiratory distress syndrome: 1, 2, 3
- acute respiratory distress syndrome and additional information: 1, 2, 3, 4, 5
- acute respiratory distress syndrome and additional molecular target: 1
- acute respiratory distress syndrome and additional therapy: 1, 2
Co phrase search for related documents, hyperlinks ordered by date